The global Chimeric Antigen Receptor (CAR) T-cell therapy market would be US$ 1,295.3 million in 2021 to US$ 9,573.6 million by 2028 at a CAGR of 33 % for the period of 2021 - 2030. Chimeric antigen reception (CAR) T- cells refers to the T- cells which are genetically modified producing artificial T- cell for immunotherapy. Patient’s cell is changed in the lab which binds to the antigen and further kill the cancer cells via infusion of modified T- cells in the patient’s body.
Increasing clinical effectiveness for chimeric antigen reception (CAR) T- cell therapy for lymphoblastic leukaemia, hematological malignancies and large B- cell lymphomas lead to the growth of CAR T- cell therapy market. Increasing partnership between academic institutes and research centers with various pharmaceutical & biopharmaceutical companies is serving in clinical assessment of various potential cancer therapies and also manages R&D expenditure. Growing cases of patients and rising clinical response for better disease reduction prolongs to decline in patients survival. CAR T- cell market is witnessing further growth due rising financial support being provided by various organisation for promoting the development and usage of CAR T- cell therapy. In 2019, Ministry pf Business, Innovation & Employment of New Zealand declared US$ 4.9 million to support for R&D of T- cell therapy and treatment of lymphoblastic leukaemia. High treatment cost for T- cell therapy hinders the growth of the market. According to Health Leaders, cost of one CAR-T therapy up to US$ 375,000 restricting the CAR-T therapy growth.
The global Chimeric Antigen Reception (CAR) T- cell therapy market is segmented by indication, product type, end- user and region. By Indication, it is categorised into acute lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, multiple myeloma and others. Based on product type, it is categorised into tisagenleceucel, lisocabtagene maraleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, ideacabtagene vicleucel and others. Usage by end- user is bifurcated into cancer treatment centers, hospitals and others. By regional aspects it is categorised into North America (US, Canada, Rest of America), Asia Pacific (India, China, Rest of Asia Pacific), Europe (UK, Germany, Russia, Rest of Europe) and Rest of the world (Latin America and Middle East & Africa).
Key players involved in the global chimeric antigen reception (CAR) T-cell therapy market are Bristol-Myers Squibb, Gilead Sciences, Inc., Sorrento Therapeutics, Inc., Amgen, Inc., Novartis AG, bluebird bio, Inc., Johnson & Johnson, Merck & Co., Inc., and Pfizer, Inc. among others.
Segmentation and Scope of the Global Chimeric Antigen Reception (CAR) T- cell Therapy Market
Global Chimeric Antigen Reception (CAR) T- cell Therapy market is segmented into indication, product type, end- user and region
By Product Type
By End User
Prominent players in the Global Chimeric Antigen Reception (CAR) T- cell Therapy market includes